Compounded Tirzepatide (GLP-1/GIP)

How tirzepatide works

Tirzepatide is a dual agonist, it activates two gut-hormone receptors, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). By targeting both pathways, it helps regulate appetite, slow digestion, and support blood-sugar control.

Like semaglutide, it's a once-weekly subcutaneous injection with a structured titration schedule set by your provider to balance effectiveness and tolerability.

What makes it "compounded"

Compounded tirzepatide is prepared by a licensed compounding pharmacy. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety or effectiveness. They are dispensed only pursuant to a valid prescription from a licensed provider for an individual patient.

At a glance

Class Dual GLP-1 / GIP receptor agonist
Form Subcutaneous injection
Frequency Once weekly
Dosing Gradual titration, provider-set
Goal Appetite regulation & weight management

See if I qualify

Semaglutide vs. tirzepatide

Your provider helps you choose. Here's a quick comparison.

GLP-1

Semaglutide

Targets GLP-1 receptor
Schedule Once weekly
Best for Many first-time GLP-1 patients

GLP-1 + GIP

Tirzepatide

Targets GLP-1 + GIP receptors
Schedule Once weekly
Best for Those who may benefit from dual-pathway therapy

Safety: Do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Common side effects include nausea, GI changes, and fatigue. Seek care for severe abdominal pain or signs of an allergic reaction. Review all risks and warnings with your provider, this is not a complete list.

Find out if tirzepatide fits your plan

Start the assessment